The authors have concluded that the formation of domains with distinct content of FPh-prm/DPPC may be associated with an inhibition of the glycoprotein P (P-gp) activity in cancer cells, which decreases the transport of chemotherapeutic drugs to the outside of cell membrane [24]. The gene discussed is PGP; the disease is cancer.